Abstract：
We investigated the predictive capacity of six prognostic indices [Karnofsky Performance Status (KPS), Hematopoietic Cell Transplant-Specific Comorbidity Index (HCT-CI), Disease Risk Index (DRI), European Bone Marrow Transplantation (EBMT) and Revised Pre-Transplantation Assessment of Mortality (rPAM) Scores and Endothelial Activation and Stress Index (EASIX)] in 205 adults undergoing post-transplant cyclophosphamide (PTCy)-based allo-HCT. KPS, HCT-CI, DRI and EASIX grouped patients into higher and lower risk strata. KPS and EASIX maintained appropriate discrimination for OS prediction across the first 2 years after allo-HCT [receiver operating characteristic curve (area under the curve (AUC) > 55 %)]. The discriminative capacity of DRI and HCT-CI increased during the post-transplant period, with a peak of prediction at 2 years (AUC of 61.1 % and 61.8 %). The maximum rPAM discriminative capacity was at 1 year (1-year AUC of 58.2 %). The predictive capacity of the EBMT score was not demonstrated. This study validates the discrimination capacity for OS prediction of KPS, HCT-CI, DRI and EASIX in PTCy-based allo-HCT.
摘要：
我们调查了六个预后指标的预测能力[Karnofsky表现状态(KPS)，造血细胞移植特异性合并症指数（HCT-CI），疾病风险指数（DRI），欧洲骨髓移植（EBMT）和修订的移植前死亡率评估（rPAM）得分和内皮激活和应激指数（EASIX）]在205名成年人中接受基于环磷酰胺（PTCy）的移植后allo-HCT。KPS,HCT-CI，DRI和EASIX将患者分为高危和低危。KPS和EASIX在allo-HCT后的前2年内保持了对OS预测的适当区分[受试者工作特征曲线(曲线下面积(AUC)>55%)]。移植后DRI和HCT-CI的辨别能力增加，预测峰值在2年(AUC为61.1%和61.8%)。rPAM的最大判别能力为1年（1年AUC为58.2％）。未证明EBMT评分的预测能力。本研究验证了KPS操作系统预测的判别能力，基于PTCy的allo-HCT中的HCT-CI、DRI和EASIX。
